Trial will aim to generate additional safety and immunogenicity data
News
NICE recommends Eli Lilly’s breast cancer drug Verzenios
Cost-effectiveness watchdog initially rejected the drug in February
Takeda takes the lead on Finch’s ulcerative colitis candidate FIN-524
The clinical development programme is now known as TAK-524
bluebird bio re-evaluates gene therapy strategy in ‘untenable’ European market
US biotech company says European payers have ‘not yet evolved their approach to gene therapy’
New joint venture aims to ‘open’ funding opportunities for early medicines discovery
Collaboration will drive medicines discovery in areas of unmet patient need
MHRA nod for Janssen’s relapsing multiple sclerosis drug Ponvory
Phase III trial showed a reduction in annual relapse rate
Santen and Sydnexis partner on childhood myopia treatment SYD-101
Phase III trials are ongoing in Europe and the US
SMC approves Bavencio for bladder cancer
The treatment was not recommended by NICE for the NHS in England
UK approval for Epidyolex to treat seizures from tuberous sclerosis
Approval represents a new indication for GW’s cannabidiol in the UK
Entry closing in 1 month for the 2021 Marketer of the Year
The 2021 Marketer of the Year competition will be closing for entry on the 10th of September.
Enhertu improves progression-free survival in breast cancer trial
Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer
US approval for Sanofi’s late-onset Pompe disease med Nexviazyme
The enzyme replacement therapy is designed to target the key mannose-6-phosphate receptor pathway
Interim trial data for UCB’s bimekizumab shows positive results
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease
Approval based on DAPA-CKD Phase III data
Finalists announced for CROY 2021
The finalists have been confirmed for the 2021 Clinical Researcher of the Year – The Americas competition.
